ORCHESTRA德尔菲共识:脆弱人群中新冠感染后状况的诊治管理
该共识基于文献综述与三轮匿名德尔菲调查(15个问题、69位专家),针对HIV感染者、风湿性疾病及血液系统恶性肿瘤患者的新冠感染后状况(PCC)提出11条共识声明。共识涉及PCC特征与危险因素、诊断与管理、预防三方面,强调慢性疲劳是最常见表现,并建议对脆弱人群采取个体化策略。
要点
- 慢性疲劳是HIV感染者与风湿性疾病患者PCC最常见表现,风湿病人群需不同的PCC病例定义。
- PCC危险因素包括年龄>65岁、新冠病情严重程度及女性,女性还与嗅觉/味觉损害增加相关。
- 建议全程接种疫苗并早期治疗新冠以预防PCC,急性感染期不推荐使用糖皮质激素。
核心结论
- 共识认为PCC在选定临床脆弱人群中的诊断、管理与预防仍存讨论,德尔菲方法提供了有价值见解,并建议对脆弱人群采取个体化策略。
研究设计与样本
- 基于文献综述确定HIV感染者、血液系统恶性肿瘤及风湿性疾病患者PCC的三方面议题,开展三轮匿名德尔菲调查,共15个问题、69位专家参与;共识以六点李克特量表分为强烈不同意、中度不同意、中度同意和强烈同意四个层级,对达成共识的问题生成声明。
主要发现
- 共生成11条声明:6条关于临床脆弱人群PCC的特征与危险因素,2条关于诊断与管理,3条关于预防。
- 慢性疲劳被确定为HIV感染者与风湿性疾病人群中PCC最常见的表现。
- 风湿性疾病人群需要不同的PCC病例定义,因PCC症状与自身免疫性疾病症状可能重叠。
- PCC危险因素包括年龄>65岁、新冠病情严重程度和女性;女性还与嗅觉/味觉损害增加相关。
- 对于HIV感染者,不建议在急性感染后3个月进行临床评估或常规实验室检查来诊断PCC;HIV感染者与风湿性疾病患者若新发慢性疲劳/关节痛,应筛查以排除其他自身免疫性疾病。
关键数值与推荐
- 推荐全程接种疫苗并早期治疗新冠以预防PCC。
- 急性感染期不推荐使用糖皮质激素。
- 不建议以急性感染后3个月的临床评估或常规实验室检查诊断HIV感染者的PCC。
- HIV感染者与风湿性疾病患者新发慢性疲劳/关节痛时应筛查排除其他自身免疫性疾病。
- 风湿性疾病人群需要不同于通用定义的PCC病例定义。
临床怎么用
- 对HIV感染者、风湿性疾病及血液系统恶性肿瘤等临床脆弱人群应关注PCC,慢性疲劳为最常见表现。
- 对上述人群应促进新冠疫苗全程接种与早期治疗以预防PCC,急性感染期不推荐糖皮质激素。
- HIV感染者不以急性感染后3个月临床评估或常规实验室检查诊断PCC;新发慢性疲劳/关节痛者应筛查排除其他自身免疫病。
- 作者建议对脆弱人群采取个体化诊疗策略。
局限性
- 原文指出PCC的诊断、管理与预防仍在讨论中。
- 原文指出德尔菲方法提供的是对选定临床脆弱人群的见解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Post-COVID-19 condition (PCC) remains poorly understood, especially in clinically vulnerable groups. We applied the Delphi approach to drive recommendations for the diagnosis, management, and prevention of PCC in people living with HIV (PWH) and patients affected by rheumatological diseases (RD) and haematological malignancies. METHODS: On the basis of literature review, three areas of interest in PCC in PWH, haematological malignancies, and RD were identified: (a) features and risk factors; (b) diagnosis and management; and (c) prevention. A three-round Delphi anonymous survey consisting of 15 questions was conducted including 69 experts. Consensus was measured by the six-point Likert scale categorized into four tiers: strong disagreement, moderate disagreement, moderate agreement, and strong agreement. Statements were generated on questions achieving consensus. RESULTS: Eleven statements were generated: six on features and risk factors of PCC in clinically vulnerable populations, two on diagnosis and management, and three on prevention. Chronic fatigue was identified as the most frequent presentation of PCC in PWH and RD populations. A different case definition of PCC is required for RD population, as symptoms of PCC and autoimmune disorders may overlap. Risk factors for PCC include age >65, severity of COVID-19, and female sex; the latter is also associated with increased smell/taste impairment. A clinical assessment or a routine laboratory test performed 3 months after acute infection is not suggested to diagnose PCC in PWH. PWH and RD should be screened to exclude additional autoimmune disorders in case of chronic fatigue/arthralgia of new onset. Full-course vaccination and early treatment for COVID-19 should be promoted to prevent PCC, whereas corticosteroids during acute infection are not recommended. DISCUSSION: Diagnosis, management, and prevention of PCC are still under discussion. This Delphi offers valuable insights on PCC in selected clinically vulnerable populations and suggests a tailored approach in vulnerable populations.
引用
- Gentilotti E, Canziani LM, Caponcello MG, et al. ORCHESTRA Delphi consensus: diagnostic and therapeutic management of post-COVID-19 condition in vulnerable populations. Clin Microbiol Infect. 2025. PMID: 40252805. doi:10.1016/j.cmi.2025.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。